Last reviewed · How we verify
NCT06632886
AI-Assisted Non-Contrast CT for Multi-Cancer Screening
NA trial testing AI-Assisted Non-Contrast CT for Multi-Cancer Screening in Lung Cancers in 1,000,000 participants. Currently enrolling.
7 October 2026
Quick facts
| Lead sponsor | Guo ShiWei |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 1,000,000 |
| Start date | 7 October 2024 |
| Primary completion | 7 October 2026 |
| Estimated completion | 7 October 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- AI-Assisted Non-Contrast CT for Multi-Cancer Screening
Conditions studied
- Lung Cancers — all drugs for Lung Cancers →
- Liver Cancer — all drugs for Liver Cancer →
- Gastric Cancers — all drugs for Gastric Cancers →
- Colorectal, Cancer — all drugs for Colorectal, Cancer →
Sponsor
Guo ShiWei
Who can join
18 and older, any sex, with Lung Cancers or Liver Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cancer poses a major public health challenge in China. Early detection can improve treatment outcomes and survival rates. In this study, we will conduct a large-scale, prospective, multi-center cohort study to evaluate the utility of AI-assisted non-contrast CT for multi-cancer screening. The study aims to enroll 1 million asymptomatic participants undergoing routine health examinations, using an AI imaging model based on non-contrast CT to detect seven cancers such as lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancers. Positive cases will be required to be referred to Shanghai Changhai Hospital for further imaging and care based on National Comprehensive Cancer Network (NCCN) and American College of Radiology (ACR) guidelines. The goal is to assess the AI model's diagnostic performance for seven cancer types, especially for early-stage, resectable tumors.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current Role of Artificial Intelligence in the Management of Gastric Cancer.
Liatsou E, Driva TS, Vergadis C, Sakellariou S, et al · · 2025 · PMID 41462951 · DOI 10.3390/biomedicines13122939
Verify or expand the search:
- PubMed search for NCT06632886
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancers
Currently open trials in the same condition.
- NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06794125 — An Evaluation of Dose-escalation for Intrathoracic Tumours · NA · recruiting
- NCT07057648 — Shape-Sensing Robotic-Assisted Bronchoscopy for Diagnosis of Peripheral Pulmonary Nodules in Korea · recruiting
- NCT06926140 — Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer · NA · recruiting
- NCT07064395 — Bright Light Therapy on Sleep Health in Lung Cancer Patients · NA · recruiting
Other Guo ShiWei trials
Trials by the same sponsor.
- NCT07329920 — Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conve · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06632886 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guo ShiWei
- Last refreshed: 9 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06632886.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing